Obaishi H, et al. Frabin, a novel FGD1-related actin filament-binding protein capable of changing cell shape and activating c-Jun N-terminal kinase. J Biol Chem. 1998;273(30):18697–700.
Article
CAS
PubMed
Google Scholar
Horn M, et al. Myelin is dependent on the Charcot-Marie-tooth type 4H disease culprit protein FRABIN/FGD4 in Schwann cells. Brain. 2012;135(12):3567–83.
Article
PubMed
PubMed Central
Google Scholar
Takai Y, Sasaki T, Matozaki T. Small GTP-binding proteins. Physiol Rev. 2001;81(1):153–208.
Article
CAS
PubMed
Google Scholar
Hall A. Rho GTPases and the control of cell behaviour. Biochem Soc Trans. 2005;33(5):891–5.
Article
CAS
PubMed
Google Scholar
Nakanishi H, Takai Y. Frabin and other related Cdc42-specific guanine nucleotide exchange factors couple the actin cytoskeleton with the plasma membrane. J Cell Mol Med. 2008;12(4):1169–76.
Article
CAS
PubMed
PubMed Central
Google Scholar
Lemmon MA. Pleckstrin homology domains: not just for phosphoinositides. Biochem Soc Trans. 2004;32(5):707–11.
Article
CAS
PubMed
Google Scholar
Rossman KL, et al. A crystallographic view of interactions between Dbs and Cdc42: PH domain-assisted guanine nucleotide exchange. EMBO J. 2002;21(6):1315–26.
Article
CAS
PubMed
PubMed Central
Google Scholar
Kutateladze TG. Phosphatidylinositol 3-phosphate recognition and membrane docking by the FYVE domain. Biochim Biophys Acta. 2006;1761(8):868–77.
Article
CAS
PubMed
PubMed Central
Google Scholar
Ikeda W, et al. Cooperation of Cdc42 small G protein-activating and actin filament-binding activities of frabin in microspike formation. Oncogene. 2001;20(27):3457–63.
Article
CAS
PubMed
Google Scholar
Ono Y, et al. Two actions of frabin: direct activation of Cdc42 and indirect activation of Rac. Oncogene. 2000;19(27):3050–8.
Article
CAS
PubMed
Google Scholar
Baudot C, et al. Two novel missense mutations in FGD4/FRABIN cause Charcot-Marie-tooth type 4H (CMT4H). J Peripher Nerv Syst. 2012;17(2):141–6.
Article
CAS
PubMed
Google Scholar
Delague V, et al. Mutations in FGD4 encoding the rho GDP/GTP exchange factor FRABIN cause autosomal recessive Charcot-Marie-tooth type 4H. Am J Hum Genet. 2007;81(1):1–16.
Article
CAS
PubMed
PubMed Central
Google Scholar
Stendel C, et al. Peripheral nerve demyelination caused by a mutant rho GTPase guanine nucleotide exchange factor, frabin/FGD4. Am J Hum Genet. 2007;81(1):158–64.
Article
CAS
PubMed
PubMed Central
Google Scholar
Qin J, et al. Upregulation of PIP3-dependent Rac exchanger 1 (P-Rex1) promotes prostate cancer metastasis. Oncogene. 2009;28(16):1853–63.
Article
CAS
PubMed
PubMed Central
Google Scholar
Lyons LS, Burnstein KL. Vav3, a rho GTPase guanine nucleotide exchange factor, increases during progression to androgen independence in prostate cancer cells and potentiates androgen receptor transcriptional activity. Mol Endocrinol. 2006;20(5):1061–72.
Article
CAS
PubMed
Google Scholar
Rao S, et al. A novel nuclear role for the Vav3 nucleotide exchange factor in androgen receptor coactivation in prostate cancer. Oncogene. 2012;31(6):716–27.
Article
CAS
PubMed
Google Scholar
Chadee DN, Kyriakis JM. MLK3 is required for mitogen activation of B-Raf, ERK and cell proliferation. Nat Cell Biol. 2004;6(8):770–6.
Article
CAS
PubMed
Google Scholar
Abo A, et al. PAK4, a novel effector for Cdc42Hs, is implicated in the reorganization of the actin cytoskeleton and in the formation of filopodia. EMBO J. 1998;17(22):6527–40.
Article
CAS
PubMed
PubMed Central
Google Scholar
Wilkinson S, Paterson HF, Marshall CJ. Cdc42-MRCK and rho-ROCK signalling cooperate in myosin phosphorylation and cell invasion. Nat Cell Biol. 2005;7(3):255–61.
Article
CAS
PubMed
Google Scholar
Sumi T, et al. Activation of LIM kinases by myotonic dystrophy kinase-related Cdc42-binding kinase alpha. J Biol Chem. 2001;276(25):23092–6.
Article
CAS
PubMed
Google Scholar
Jemal A, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58(2):71–96.
Article
PubMed
Google Scholar
Rastinehad AR, et al. Improving detection of clinically significant prostate cancer: magnetic resonance imaging/transrectal ultrasound fusion guided prostate biopsy. J Urol. 2014;191(6):1749–54.
Article
PubMed
Google Scholar
Welch HG, Albertsen PC. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. J Natl Cancer Inst. 2009;101(19):1325–9.
Article
PubMed
PubMed Central
Google Scholar
Thompson I, et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol. 2007;177(6):2106–31.
Article
PubMed
Google Scholar
Klotz L, Emberton M. Management of low risk prostate cancer-active surveillance and focal therapy. Nat Rev Clin Oncol. 2014;11(6):324–34.
Article
PubMed
Google Scholar
Simmons MN, Stephenson AJ, Klein EA. Natural history of biochemical recurrence after radical prostatectomy: risk assessment for secondary therapy. Eur Urol. 2007;51(5):1175–84.
Article
PubMed
Google Scholar
Rosenbaum E, Partin A, Eisenberger MA. Biochemical relapse after primary treatment for prostate cancer: studies on natural history and therapeutic considerations. J Natl Compr Cancer Netw. 2004;2(3):249–56.
Article
Google Scholar
de Bono JS, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364(21):1995–2005.
Article
CAS
PubMed
PubMed Central
Google Scholar
Bilgin B, et al. Docetaxel or abiraterone in addition to androgen deprivation therapy in metastatic castration-sensitive prostate cancer. Future Oncol. 2017;13:1911-13.
Gravina GL, et al. Hormonal therapy promotes hormone-resistant phenotype by increasing DNMT activity and expression in prostate cancer models. Endocrinology. 2011;152(12):4550–61.
Article
CAS
PubMed
PubMed Central
Google Scholar
Harris WP, et al. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol. 2009;6(2):76–85.
Article
CAS
PubMed
PubMed Central
Google Scholar
Ottman R, et al. MicroRNA expressions associated with progression of prostate cancer cells to antiandrogen therapy resistance. Mol Cancer. 2014;13:1.
Article
PubMed
PubMed Central
Google Scholar
Allred DC, et al. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst. 1993;85(3):200–6.
Article
CAS
PubMed
Google Scholar
Kokontis J, et al. Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation. Cancer Res. 1994;54(6):1566–73.
CAS
PubMed
Google Scholar
Wu HC, et al. Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells. Int J Cancer. 1994;57(3):406–12.
Article
CAS
PubMed
Google Scholar
Ottman R, et al. The other face of miR-17-92a cluster, exhibiting tumor suppressor effects in prostate cancer. Oncotarget. 2016;7(45):73739–53.
Article
PubMed
PubMed Central
Google Scholar
Beltran H, et al. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat Med. 2016;22(3):298–305.
Article
CAS
PubMed
PubMed Central
Google Scholar
Gao, J., et al., Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6(269):l1.
Medici D, Hay ED, Olsen BR. Snail and Slug promote epithelial-mesenchymal transition through beta-catenin-T-cell factor-4-dependent expression of transforming growth factor-beta3. Mol Biol Cell. 2008;19(11):4875–87.
Article
CAS
PubMed
PubMed Central
Google Scholar
Cavallaro U, Christofori G. Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat Rev Cancer. 2004;4(2):118–32.
Article
CAS
PubMed
Google Scholar
Baskaran Y, et al. Group I and II mammalian PAKs have different modes of activation by Cdc42. EMBO Rep. 2012;13(7):653–9.
Article
CAS
PubMed
PubMed Central
Google Scholar
Yang N, et al. Cofilin phosphorylation by LIM-kinase 1 and its role in Rac-mediated actin reorganization. Nature. 1998;393(6687):809–12.
Article
CAS
PubMed
Google Scholar
Ahmed T, et al. A PAK4-LIMK1 pathway drives prostate cancer cell migration downstream of HGF. Cell Signal. 2008;20(7):1320–8.
Article
CAS
PubMed
Google Scholar
Liu HP, et al. Epstein-Barr virus-encoded LMP1 interacts with FGD4 to activate Cdc42 and thereby promote migration of nasopharyngeal carcinoma cells. PLoS Pathog. 2012;8(5):e1002690.
Article
CAS
PubMed
PubMed Central
Google Scholar
Ko HK, et al. Suppression of chemotaxis by SSeCKS via scaffolding of phosphoinositol phosphates and the recruitment of the Cdc42 GEF, Frabin to the leading edge. PLoS One. 2014;9(10):e111534.
Article
PubMed
PubMed Central
Google Scholar
Dong Z, et al. Vav3 oncogene is overexpressed and regulates cell growth and androgen receptor activity in human prostate cancer. Mol Endocrinol. 2006;20(10):2315–25.
Article
CAS
PubMed
Google Scholar
Rodriguez-Fraticelli AE, et al. The Cdc42 GEF Intersectin 2 controls mitotic spindle orientation to form the lumen during epithelial morphogenesis. J Cell Biol. 2010;189(4):725–38.
Article
CAS
PubMed
PubMed Central
Google Scholar
Kodani A, et al. GM130-dependent control of Cdc42 activity at the Golgi regulates centrosome organization. Mol Biol Cell. 2009;20(4):1192–200.
Article
CAS
PubMed
PubMed Central
Google Scholar
Yasuda S, et al. Cdc42 and mDia3 regulate microtubule attachment to kinetochores. Nature. 2004;428(6984):767–71.
Article
CAS
PubMed
Google Scholar
Kaji N, Muramoto A, Mizuno K. LIM kinase-mediated cofilin phosphorylation during mitosis is required for precise spindle positioning. J Biol Chem. 2008;283(8):4983–92.
Article
CAS
PubMed
Google Scholar
Huang SL, Chao CC. Silencing of Taxol-sensitizer genes in Cancer cells: lack of sensitization effects. Cancers (Basel). 2015;7(2):1052–71.
Article
CAS
Google Scholar
Lu S, et al. Preferential induction of G1 arrest in androgen-responsive human prostate cancer cells by androgen receptor signaling antagonists DL3 and antiandrogen bicalutamide. Cancer Lett. 2010;298(2):250–7.
Article
CAS
PubMed
PubMed Central
Google Scholar
Murthy S, et al. Role of androgen receptor in progression of LNCaP prostate cancer cells from G1 to S phase. PLoS One. 2013;8(2):e56692.
Article
CAS
PubMed
PubMed Central
Google Scholar
Floyd MS Jr, et al. Differential mechanisms of bicalutamide-induced apoptosis in prostate cell lines. Prostate Cancer Prostatic Dis. 2009;12(1):25–33.
Article
PubMed
Google Scholar